JP2024513988A5 - - Google Patents
Info
- Publication number
- JP2024513988A5 JP2024513988A5 JP2023562998A JP2023562998A JP2024513988A5 JP 2024513988 A5 JP2024513988 A5 JP 2024513988A5 JP 2023562998 A JP2023562998 A JP 2023562998A JP 2023562998 A JP2023562998 A JP 2023562998A JP 2024513988 A5 JP2024513988 A5 JP 2024513988A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- oxy
- amino
- propan
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/087655 | 2021-04-16 | ||
| CN2021087655 | 2021-04-16 | ||
| US202263311231P | 2022-02-17 | 2022-02-17 | |
| US63/311,231 | 2022-02-17 | ||
| PCT/IB2022/053454 WO2022219546A1 (en) | 2021-04-16 | 2022-04-13 | Heteroaryl aminopropanol derivatives as inhibitors of lta4h |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513988A JP2024513988A (ja) | 2024-03-27 |
| JP2024513988A5 true JP2024513988A5 (https=) | 2025-04-22 |
Family
ID=81346222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562998A Pending JP2024513988A (ja) | 2021-04-16 | 2022-04-13 | Ｌｔａ４ｈの阻害剤としてのヘテロアリールアミノプロパノール誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11932630B2 (https=) |
| EP (2) | EP4628163A1 (https=) |
| JP (1) | JP2024513988A (https=) |
| KR (1) | KR20230172533A (https=) |
| CN (1) | CN117015537A (https=) |
| AU (1) | AU2022259056A1 (https=) |
| BR (1) | BR112023019043A2 (https=) |
| CA (1) | CA3210344A1 (https=) |
| ES (1) | ES3049013T3 (https=) |
| MX (1) | MX2023012211A (https=) |
| PY (1) | PY2228191A (https=) |
| TW (1) | TW202304429A (https=) |
| WO (1) | WO2022219546A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI828839B (zh) * | 2019-01-11 | 2024-01-11 | 瑞士商諾華公司 | 使用lta4h抑制劑治療化膿性汗腺炎之方法 |
| US11932630B2 (en) * | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| CN115785014B (zh) * | 2022-12-27 | 2025-01-24 | 瑞石生物医药有限公司 | 四唑衍生物及其用途 |
| CN120365187B (zh) * | 2025-04-23 | 2025-10-10 | 辽宁众辉生物科技有限公司 | 一种一锅法合成杀菌剂中间体肟醚的方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200424183A (en) | 2002-08-09 | 2004-11-16 | Nps Pharma Inc | New compounds |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| JP3493359B1 (ja) | 2003-03-20 | 2004-02-03 | 宣美 辛島 | イオン泳動式治療装置 |
| ATE403654T1 (de) * | 2003-07-28 | 2008-08-15 | Janssen Pharmaceutica Nv | Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren |
| EP2066800A2 (en) * | 2006-08-04 | 2009-06-10 | Decode Genetics EHF | Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation |
| TW200906396A (en) * | 2007-02-14 | 2009-02-16 | Janssen Pharmaceutica Nv | LTA4H modulators and uses thereof |
| WO2010062829A1 (en) | 2008-11-28 | 2010-06-03 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for treating osteoporosis |
| EP2582666B1 (en) * | 2010-06-16 | 2014-08-13 | Purdue Pharma L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
| JP6080227B2 (ja) | 2012-03-06 | 2017-02-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成を阻害するためのベンゾジオキサン |
| WO2015009609A1 (en) | 2013-07-15 | 2015-01-22 | Boehringer Ingelheim International Gmbh | Inhibitors of leukotriene production |
| NZ719169A (en) * | 2013-12-20 | 2018-08-31 | Novartis Ag | Heteroaryl butanoic acid derivatives as lta4h inhibitors |
| NZ734082A (en) | 2015-01-20 | 2019-01-25 | Boehringer Ingelheim Animal Health Usa Inc | Anthelmintic compounds, compositions and method of using thereof |
| WO2017175185A1 (en) | 2016-04-08 | 2017-10-12 | Novartis Ag | Heteroaryl butanoic acid derivatives as lta4h inhibitors |
| US11597706B2 (en) | 2016-04-18 | 2023-03-07 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| ES2940611T3 (es) | 2016-04-18 | 2023-05-09 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| WO2018175746A1 (en) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
| RS65492B1 (sr) | 2017-07-24 | 2024-05-31 | Novartis Ag | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp |
| CN111094242B (zh) | 2017-07-24 | 2024-02-09 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| EP3669872A4 (en) | 2017-08-18 | 2021-05-05 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | FORMYL PYRIDINE DERIVATIVE WITH PD-L1 INHIBITORING EFFECT, MANUFACTURING METHOD FOR IT AND USE THEREOF |
| EP3697758B1 (en) | 2017-10-17 | 2022-07-06 | Novartis AG | Sulphonamides and compositions thereof for treating conditions associated with nlrp activity |
| CN112654350A (zh) | 2018-07-03 | 2021-04-13 | 诺华股份有限公司 | 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法 |
| US20220267276A1 (en) | 2018-07-03 | 2022-08-25 | Novartis Ag | Nlrp modulators |
| EP3817815A1 (en) | 2018-07-03 | 2021-05-12 | Novartis AG | Nlrp modulators |
| KR20210038877A (ko) | 2018-07-25 | 2021-04-08 | 노파르티스 아게 | Nlrp3 인플라마좀 억제제 |
| CN112513026B (zh) | 2018-07-31 | 2025-02-25 | 诺华股份有限公司 | Lta4h抑制剂的晶型 |
| TW202028183A (zh) | 2018-10-10 | 2020-08-01 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
| US20220387397A1 (en) | 2018-10-24 | 2022-12-08 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| CN113056451A (zh) | 2018-10-24 | 2021-06-29 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| CR20210235A (es) | 2018-11-13 | 2021-06-30 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp |
| EP3880666B1 (en) | 2018-11-13 | 2023-06-28 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| CN113015730A (zh) | 2018-11-13 | 2021-06-22 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| US20230059136A1 (en) | 2018-11-16 | 2023-02-23 | Novartis Ag | The compounds and compositions for treating conditions associated with nlrp activity |
| CN113286784A (zh) | 2018-11-16 | 2021-08-20 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| TWI828839B (zh) | 2019-01-11 | 2024-01-11 | 瑞士商諾華公司 | 使用lta4h抑制劑治療化膿性汗腺炎之方法 |
| EP3914583A1 (en) | 2019-01-22 | 2021-12-01 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| EP3914585A1 (en) | 2019-01-23 | 2021-12-01 | Novartis AG | Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| TW202122078A (zh) * | 2019-09-06 | 2021-06-16 | 瑞士商諾華公司 | 使用lta4h抑制劑治療肝臟疾病之方法 |
| JP7545570B2 (ja) | 2020-08-14 | 2024-09-04 | ノバルティス アーゲー | ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用 |
| US11932630B2 (en) * | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
-
2022
- 2022-04-08 US US17/716,423 patent/US11932630B2/en active Active
- 2022-04-12 PY PY202202228191A patent/PY2228191A/es unknown
- 2022-04-13 MX MX2023012211A patent/MX2023012211A/es unknown
- 2022-04-13 BR BR112023019043A patent/BR112023019043A2/pt unknown
- 2022-04-13 EP EP25190714.3A patent/EP4628163A1/en active Pending
- 2022-04-13 CA CA3210344A patent/CA3210344A1/en active Pending
- 2022-04-13 WO PCT/IB2022/053454 patent/WO2022219546A1/en not_active Ceased
- 2022-04-13 KR KR1020237039149A patent/KR20230172533A/ko active Pending
- 2022-04-13 CN CN202280016925.8A patent/CN117015537A/zh active Pending
- 2022-04-13 ES ES22717931T patent/ES3049013T3/es active Active
- 2022-04-13 EP EP22717931.4A patent/EP4323062B1/en active Active
- 2022-04-13 AU AU2022259056A patent/AU2022259056A1/en active Pending
- 2022-04-13 JP JP2023562998A patent/JP2024513988A/ja active Pending
- 2022-04-14 TW TW111114222A patent/TW202304429A/zh unknown
-
2024
- 2024-01-30 US US18/426,461 patent/US20240199593A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024513988A5 (https=) | ||
| US10344016B2 (en) | Bromotriazole intermediates | |
| KR101678255B1 (ko) | 치환 아미드 화합물 | |
| US9511073B2 (en) | Aromatic amides and uses thereof | |
| BG63161B1 (bg) | Фенилхетероциклени съединения като инхибитори на циклооксигеназа-2 | |
| JP5107721B2 (ja) | ヘテロ環置換ピリジン誘導体およびそれらを含有する抗真菌剤 | |
| JPWO2008136324A1 (ja) | ヘテロ環およびホスホノアミノ基が置換したピリジン誘導体ならびにそれらを含有する抗真菌剤 | |
| WO2012102255A1 (ja) | インドール誘導体、またはその薬理学的に許容される塩 | |
| WO2012102254A1 (ja) | インドール誘導体、またはその薬理学的に許容される塩 | |
| CN107709301B (zh) | 吡唑衍生物或其药理学上可接受的盐 | |
| CN114026068A (zh) | Ep2拮抗剂 | |
| JP2023516714A (ja) | 新規ｅｐ４拮抗薬の合成及びその癌及び炎症における使用 | |
| KR100545507B1 (ko) | 복소환 유도체 | |
| JP2013147443A (ja) | β置換カルボン酸誘導体 | |
| TW202233575A (zh) | 用於治療與lpa受體活性相關的病狀的化合物及組合物 | |
| RU2023129426A (ru) | Производные гетероариламинопропанола в качестве ингибиторов lta4h | |
| WO2006095713A1 (ja) | プラスミノゲンアクチベータインヒビター－１阻害剤 | |
| JP7678114B2 (ja) | ＲＯＲγｔモジュレーター、その製造方法および応用 | |
| US6489487B1 (en) | Triazolone derivatives, use thereof, and intermediates therefor | |
| CN102947291B (zh) | 三唑酮化合物的前药 | |
| WO2016017699A1 (ja) | アゾールカルボン酸誘導体 | |
| JPH1180135A (ja) | 抗真菌トリアゾール化合物 | |
| JP2026053300A (ja) | 三環性化合物を含有する腎疾患の予防及び／又は治療剤 | |
| JP2026071419A (ja) | 三環性化合物を含有する腎疾患の予防及び／又は治療剤 | |
| KR100576337B1 (ko) | 피리다진-4-온 유도체, 그 제조방법 및 약제학적 조성물 |